Histogenics Receives $49,000,000 Series A Round

  • Feed Type
  • Date
    7/24/2012
  • Company Name
    Histogenics
  • Mailing Address
    830 Winter Street 3rd Floor Waltham, MA 02451
  • Company Description
    Histogenics is a tissue regeneration company developing breakthrough treatments for long-lasting joint repair. Its cartilage regeneration products apply advanced cell biology, tissue engineering, and materials science in the repair of injured or diseased joints, to restore joint function and prevent degenerative disease.
  • Website
    http://www.histogenics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $49,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds will be used to complete the ongoing Phase 3 clinical program for lead product candidate NeoCart, which is currently enrolling patients. NeoCart is an autologous neocartilage tissue implant that utilizes the patient’s own cells to regenerate cartilage in patients suffering from cartilage lesions in the knee. Funds will also support efforts to obtain regulatory clearance in the European Union for product candidate VeriCart, a single-step, cell-free collagen scaffold uniquely designed to be used in conjunction with the patient’s own stem cells, to repair small cartilage defects frequently observed in meniscal and anterior cruciate ligament repair procedures.
  • M&A Terms
  • Venture Investor
    Sofinnova Ventures
  • Venture Investor
    Split Rock Partners
  • Venture Investor
    GIMV
  • Venture Investor
    Inflection Point Ventures
  • Venture Investor
    Foundation Medical Partners
  • Venture Investor
    Boston Millennia Partners
  • Venture Investor
    BioMed Ventures
  • Venture Investor
    ProChon Holdings BV
  • Venture Investor
    Altima Partners

By posting a comment, you agree to our terms and conditions.